DMTs for MS in Iran include injectable drugs (β-interferons and Glatiramer acetate), oral drugs (fingolimod, Teriflunomide, and Dimethyl fumarate), and infusion drugs (natalizumab and Ocrelizumab) [28], and physicians use first-line drugs (beta interferons, glatiramer acetate, Teriflunomide, and dimethyl fumarate) for the treatment of MS [28], depending on the patients’ conditions and evaluation of the disease. This evidence concerns the gene IFNB1 and myeloid sarcoma.